收费全文 | 9672篇 |
免费 | 1073篇 |
国内免费 | 48篇 |
耳鼻咽喉 | 70篇 |
儿科学 | 341篇 |
妇产科学 | 165篇 |
基础医学 | 1219篇 |
口腔科学 | 213篇 |
临床医学 | 1256篇 |
内科学 | 2209篇 |
皮肤病学 | 148篇 |
神经病学 | 765篇 |
特种医学 | 505篇 |
外科学 | 1505篇 |
综合类 | 216篇 |
一般理论 | 9篇 |
预防医学 | 914篇 |
眼科学 | 115篇 |
药学 | 584篇 |
中国医学 | 1篇 |
肿瘤学 | 558篇 |
2023年 | 76篇 |
2021年 | 114篇 |
2020年 | 155篇 |
2019年 | 113篇 |
2018年 | 227篇 |
2017年 | 153篇 |
2016年 | 151篇 |
2015年 | 161篇 |
2014年 | 241篇 |
2013年 | 360篇 |
2012年 | 397篇 |
2011年 | 394篇 |
2010年 | 246篇 |
2009年 | 290篇 |
2008年 | 397篇 |
2007年 | 416篇 |
2006年 | 430篇 |
2005年 | 379篇 |
2004年 | 358篇 |
2003年 | 317篇 |
2002年 | 350篇 |
2001年 | 319篇 |
2000年 | 285篇 |
1999年 | 246篇 |
1998年 | 180篇 |
1997年 | 178篇 |
1996年 | 152篇 |
1995年 | 145篇 |
1994年 | 112篇 |
1993年 | 141篇 |
1992年 | 221篇 |
1991年 | 188篇 |
1990年 | 228篇 |
1989年 | 217篇 |
1988年 | 195篇 |
1987年 | 175篇 |
1986年 | 158篇 |
1985年 | 167篇 |
1984年 | 137篇 |
1983年 | 94篇 |
1982年 | 76篇 |
1981年 | 76篇 |
1979年 | 123篇 |
1978年 | 89篇 |
1976年 | 82篇 |
1975年 | 80篇 |
1974年 | 89篇 |
1973年 | 84篇 |
1972年 | 88篇 |
1969年 | 82篇 |
Background
Heterozygous NKX2-1 loss-of-function variants cause combinations of hyperkinetic movement disorders (MDs, particularly childhood-onset chorea), pulmonary dysfunction, and hypothyroidism. Mobile element insertions (MEIs) are potential disease-causing structural variants whose detection in routine diagnostics remains challenging.Objective
To establish the molecular diagnosis of two first-degree relatives with clinically suspected NKX2-1-related disorder who had negative NKX2-1 Sanger (SS), whole-exome (WES), and whole-genome (WGS) sequencing.Methods
The proband's WES was analyzed for MEIs. A candidate MEI in NKX2-1 underwent optimized SS after plasmid cloning. Functional studies exploring NKX2-1 haploinsufficiency at RNA and protein levels were performed.Results
A 347-bp AluYa5 insertion with a 65-bp poly-A tail followed by a 16-bp duplication of the pre-insertion wild-type sequence in exon 3 of NKX2-1 (ENST00000354822.7:c.556_557insAlu541_556dup) segregated with the disease phenotype.Conclusions
We identified a de novo exonic AluYa5 insertion causing NKX2-1-related disorder in SS/WES/WGS-negative cases, suggesting that MEI analysis of short-read sequencing data or targeted long-read sequencing could unmask the molecular diagnosis of unsolved MD cases. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. 相似文献Once-weekly semaglutide and dulaglutide represent two highly efficacious treatment options for type 2 diabetes. A recent indirect treatment comparison (ITC) has associated semaglutide 1 mg with similar and greater improvements in glycated haemoglobin (HbA1c) and body weight, respectively, vs. dulaglutide 3 mg and 4.5 mg. The present study aimed to evaluate the long-term cost-effectiveness of semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Materials and methodsThe IQVIA CORE Diabetes Model (v9.0) was used to project outcomes over patients’ lifetimes. Baseline cohort characteristics were sourced from SUSTAIN 7, with changes in HbA1c and body mass index applied as per the ITC. Modelled patients received semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin. Costs (expressed in 2020 pounds sterling [GBP]) were accounted from a healthcare payer perspective.
ResultsSemaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.05 and 0.04 quality-adjusted life years (QALYs) vs. dulaglutide 3 mg and 4.5 mg, respectively, due to a reduced incidence of diabetes-related complications with semaglutide. Direct costs were estimated to be GBP 76 lower and GBP 8 higher in the comparisons with dulaglutide 3 mg and 4.5 mg, respectively. Overall outcomes were similar, but favoured semaglutide, and based on modelled mean outcomes it was considered dominant vs. dulaglutide 3 mg and associated with an incremental cost-effectiveness ratio of GBP 228 per QALY gained vs. dulaglutide 4.5 mg.
ConclusionsSemaglutide 1 mg represents a cost-effective treatment vs. dulaglutide 3 mg and 4.5 mg for type 2 diabetes from a healthcare payer perspective in the UK.
相似文献